Beneficial Ownership Report · SCHEDULE 13G
Werewolf Therapeutics, Inc.
HOWLNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Werewolf Therapeutics, Inc.
- Company CIK
- 0001785530
- Street
- 303 WYMAN STREET
- Street (continued)
- SUITE 300
- City
- WALTHAM
- State / country code
- MA
- Postal code
- 02451
Statement details
- Security class
- Common stock 0,0001$ per share
- Event date
- 09/18/2026
- Rule designation
- Rule 13d-1(d)
Reporting person 1
- Name
- MOLL PETER
- Citizenship / organization
- 2M
- Reporting person type
- OO
- Aggregate amount owned
- 2,537,138.00
- Percent of class
- 5.2
- Sole voting power
- 2,537,138.00
- Shared voting power
- 0.00
- Sole dispositive power
- 2,537,138.00
- Shared dispositive power
- 0.00
- Comments
- Private Investor
Item 1
Issuer
Werewolf Therapeutics, Inc.
Principal executive office address
303 WYMAN STREET, SUITE 300, WALTHAM, MASSACHUSETTS, 02451
Item 2
Citizenship
German
Filing person
Peter Moll
Principal business or residence address
Degelestr. 3, 01324 Dresden, Germany
Item 3
Not applicable indication
Y
Item 4
Percent of class
5.2
Amount beneficially owned
2537138
Sole voting power
2537138
Shared voting power
5.2
Sole dispositive power
2537138
Shared dispositive power
0
Item 5
Not applicable indication
Y
Ownership of 5% or less
N
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature comments
Peter Moll
Signature 1
- Reporting person
- MOLL PETER
- Signed
- PeterMoll
- Title
- Owner
- Date
- 09/21/2026
Company context
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company has designed conditionally activated INDUKINETM molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. To learn more visit www.werewolftx.com.